-
Something wrong with this record ?
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group
J. Minarik, V. Sandecka, V. Maisnar, E. Gregora, I. Spicka, D. Starostka, H. Plonkova, J. Jarkovsky, L. Walterova, M. Wrobel, D. Adamova, T. Pika, H. Melicharova, L. Pour, J. Radocha, P. Pavlicek, J. Straub, J. Gumulec, J. Bacovsky, Z. Adam, V....
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12215
MZ0
CEP Register
NT14393
MZ0
CEP Register
- MeSH
- Time Factors MeSH
- Cyclophosphamide administration & dosage MeSH
- Dexamethasone administration & dosage MeSH
- Adult MeSH
- Remission Induction MeSH
- Boronic Acids administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Melphalan administration & dosage MeSH
- Survival Rate MeSH
- Young Adult MeSH
- Multiple Myeloma drug therapy mortality MeSH
- Follow-Up Studies MeSH
- Prednisone administration & dosage MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrazines administration & dosage MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Thalidomide administration & dosage MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040666
- 003
- CZ-PrNML
- 005
- 20191108090941.0
- 007
- ta
- 008
- 140107s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2013.06.019 $2 doi
- 035 __
- $a (PubMed)23845888
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Minařík, Jiří $7 xx0106330
- 245 10
- $a 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group / $c J. Minarik, V. Sandecka, V. Maisnar, E. Gregora, I. Spicka, D. Starostka, H. Plonkova, J. Jarkovsky, L. Walterova, M. Wrobel, D. Adamova, T. Pika, H. Melicharova, L. Pour, J. Radocha, P. Pavlicek, J. Straub, J. Gumulec, J. Bacovsky, Z. Adam, V. Scudla, R. Hajek,
- 520 9_
- $a We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a kyseliny boronové $x aplikace a dávkování $7 D001897
- 650 _2
- $a cyklofosfamid $x aplikace a dávkování $7 D003520
- 650 _2
- $a dexamethason $x aplikace a dávkování $7 D003907
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melfalan $x aplikace a dávkování $7 D008558
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prednison $x aplikace a dávkování $7 D011241
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a pyraziny $x aplikace a dávkování $7 D011719
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a thalidomid $x aplikace a dávkování $7 D013792
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sandecká, Viera $7 xx0129325
- 700 1_
- $a Maisnar, Vladimír $7 xx0062937
- 700 1_
- $a Gregora, Evžen $7 xx0171063
- 700 1_
- $a Špička, Ivan, $d 1960- $7 jn20001103644
- 700 1_
- $a Starostka, David $7 xx0141608
- 700 1_
- $a Plonková, Hana $7 xx0171719
- 700 1_
- $a Jarkovský, Jiří $7 stk2008461294
- 700 1_
- $a Walterová, Lenka $7 xx0098378
- 700 1_
- $a Wróbel, Marek $7 xx0303976
- 700 1_
- $a Adamová, Dagmar $7 _AN051683
- 700 1_
- $a Pika, Tomáš $7 xx0071238
- 700 1_
- $a Melicharova, Hana $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Pour, Luděk $7 xx0102556
- 700 1_
- $a Radocha, Jakub, $d 1981- $7 xx0233189
- 700 1_
- $a Pavlíček, Petr $u - $7 xx0128184
- 700 1_
- $a Straub, Jan $7 xx0080316
- 700 1_
- $a Gumulec, Jaromír, $d 1963- $7 xx0054104
- 700 1_
- $a Bačovský, Jaroslav $7 xx0053311
- 700 1_
- $a Adam, Zdeněk, $d 1953- $7 jn19981000018
- 700 1_
- $a Scudla, Vlastimil $u -
- 700 1_
- $a Hajek, Roman $u -
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 37, č. 9 (2013), s. 1063-1069
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23845888 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20191108091213 $b ABA008
- 999 __
- $a ok $b bmc $g 1005062 $s 839178
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 37 $c 9 $d 1063-1069 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- GRA __
- $a NT12215 $p MZ0
- GRA __
- $a NT14393 $p MZ0
- LZP __
- $a Pubmed-20140107